Candida and Candidaemia: Susceptibility and Epidemiology

Danish Medical Journal

Volumn 60, Issue 11, 2013, Pages

  Arendrup, Maiken Cavling ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; HOST FACTOR; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TERBINAFINE; VORICONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT;

AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDEMIA; DISK DIFFUSION; DRUG POTENCY; FUNGAL COLONIZATION; FUNGAL VIRULENCE; GROUPS BY AGE; GROWTH INHIBITION; HUMAN; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PREDICTION; SPECIES DISTRIBUTION; DENMARK; DRUG EFFECT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; REVIEW;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; DENMARK; ECHINOCANDINS; FLUCONAZOLE; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS;

EID: 84887386047     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (122)

1. Arendrup, M., T. Horn, and N. Frimodt-Moller. 2002. In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection 30:286-291.
2. Arendrup, M., B. Lundgren, I. M. Jensen, B. S. Hansen, and N. Frimodt-Moller. 2001. Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates. J. Antimicrob. Chemother. 47:521-526.
3. Arendrup, M. C., G. Kahlmeter, J. L. Rodriguez-Tudela, and J. P. Donnelly. 2009. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob. Agents Chemother. 53:1628-1629.
4. Arendrup, M. C., G. Garcia-Effron, W. Buzina, K. L. Mortensen, N. Reiter, C. Lundin, H. E. Jensen, C. Lass-Florl, D. S. Perlin, and B. Bruun. 2009. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob. Agents Chemother. 53:1185-1193.
5. Arendrup, M. C., G. Garcia-Effron, C. Lass-Florl, A. G. Lopez, J. L. Rodriguez-Tudela, M. Cuenca-Estrella, and D. S. Perlin. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob. Agents Chemother. 54:426-439.
6. Arendrup, M. C., J. L. Rodriguez-Tudela, S. Park, G. Garcia-Effron, G. Delmas, M. Cuenca-Estrella, L. A. Gomez, and D. S. Perlin. 2011. Echinocandin susceptibility testing of Candida spp. using the EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: Analysis of the influence of Bovine Serum Albumin Supplementation, Storage Time and Drug Lots. Antimicrob Agents Chemother. 55:1580-1587.
7. Arendrup, M. C., K. Fuursted, B. Gahrn-Hansen, I. M. Jensen, J. D. Knudsen, B. Lundgren, H. C. Schonheyder, and M. Tvede. 2005. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J. Clin. Microbiol. 43:4434-4440.
8. Arendrup, M. C., B. Bruun, J. J. Christensen, K. Fuursted, H. K. Johansen, P. Kjaldgaard, J. D. Knudsen, L. Kristensen, J. Moller, L. Nielsen, F. S. Rosenvinge, B. Roder, H. C. Schonheyder, M. K. Thomsen, and K. Truberg. 2011. National Surveillance of Fungemia in Denmark 2004-2009. Journal of Clinical Microbiology 49:325-334.
9. Arendrup, M. C., S. Sulim, A. Holm, L. Nielsen, S. D. Nielsen, J. D. Knudsen, N. E. Drenck, J. J. Christensen, and H. K. Johansen. 2011. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin. Microbiol 49:3300-3308.
10. Nielsen, H., J. Stenderup, and B. Bruun. 1991. Fungemia in a university hospital 1984-1988. Clinical and mycological characteristics. Scand. J Infect. Dis. 23:275-282.
11. Bruun, B., H. Westh, and J. Stenderup. 1995. Fungemia: An increasing problem in a Danish university hospital 1989 to 1994. Clin. Microbiol. Infect. 1:124-126.
12. Bruun B. 1998. Svampeinfektioner., p. 26-30. In: J. V. Christensen BE (ed.), Infektioner hos hæmatologiske og onkologiske patienter. 1 ed. Odense Universitets Forlag, Denmark, Odense.
13. Schonheyder, H. C. 2000. [Two thousands seven hundred and thirty nine episodes of bacteremia in the county of Northern Jutland 1996-1998. Presentation of a regional clinical database]. Ugeskr. Laeger 162:2886-2891.
14. Schønheyder HC. 2001. Candidæmi i Nordjyllands amt-en opfølgning. Nyt om Mikrobiologi 57:5.
15. National Committee on Clinical and Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard. CLSI document M27-A2. 1997. Clinical and laboratory Standards Institute, Pennsylvania, USA.
16. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard-Second edition. CLSI document M27-A2. 2002. Clinical and laboratory Standards Institute, Pennsylvania, USA.
17. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Second Informational Supplement. CLSI document M27-S2. 2005. Clinical and laboratory Standards Institute, Pennsylvania, USA.
18. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard-Third edition. CLSI document M27-A3. 2008. Clinical and laboratory Standards Institute, Pennsylvania, USA.
19. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Third informational Supplement. CLSI document M27-S3. 2008. Clinical and laboratory Standards Institute, Pennsylvania, USA.
20. The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on AntifungalSusceptibility Testing (EUCAST-AFST). 2008. EUCAST Technical Note on fluconazole. Clin. Microbiol. Infect. 14:193-195.
21. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee forAntimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST Technical Note on voriconazole. Clin. Microbiol Infect. 14:985-987.
22. Arendrup, M. C., J. L. Rodriguez-Tudela, C. Lass-Florl, M. Cuenca-Estrella, J. P. Donnelly, W. Hope, and The European committee on antimicrobial susceptibility testing-subcommittee on antifungal susceptibility testing (EUCASTAFST). 2011. EUCAST technical note on anidulafungin. Clinical Microbiology and Infection 17:E18-E20.
23. Lass-Florl, C., M. C. Arendrup, J. L. Rodriguez-Tudela, M. Cuenca-Estrella, P. Donnelly, W. Hope, and The European committee on antimicrobial susceptibility testing-subcommittee on antifungal susceptibility testing (EUCASTAFST). 2011. EUCAST Technical note on Amphotericin B. Clinical Microbiology and Infection 17:E27-E29.
24. Pfaller, M. A., D. Andes, D. J. Diekema, A. Espinel-Ingroff, and D. Sheehan. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
25. Pfaller, M. A., D. Andes, M. C. Arendrup, D. J. Diekema, A. Espinel-Ingroff, B. D. Alexander, S. D. Brown, V. Chaturvedi, C. L. Fowler, M. A. Ghannoum, E. M. Johnson, C. C. Knapp, M. R. Motyl, L. Ostrosky-Zeichner, and T. J. Walsh. 2011. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn. Microbiol Infect Dis 70:330-343.
26. Pfaller, M. A., D. J. Diekema, D. Andes, M. C. Arendrup, S. D. Brown, S. R. Lockhart, M. Motyl, and D. S. Perlin. 2011. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
27. Leroy, O., J. P. Gangneux, P. Montravers, J. P. Mira, F. Gouin, J. P. Sollet, J. Carlet, J. Reynes, M. Rosenheim, B. Regnier, and O. Lortholary. 2009. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 37:1612-1618.
28. Vincent, J. L., J. Rello, J. Marshall, E. Silva, A. Anzueto, C. D. Martin, R. Moreno, J. Lipman, C. Gomersall, Y. Sakr, K. Reinhart, and for the EPIC II Group of Investigators. 2009. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA 302:2323-2329.
29. Arendrup, M. C., K. Fuursted, B. Gahrn-Hansen, H. C. Schonheyder, J. D. Knudsen, I. M. Jensen, B. Bruun, J. J. Christensen, and H. K. Johansen. 2008. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 14:487-494.
30. Arendrup, M. C. and The Danish Fungaemia Study Group. 2012. National Surveillance of Fungemia in Denmark 2010-11. ICAAC abstract M318.
31. Wingard, J. R., J. D. Dick, W. G. Merz, G. R. Sandford, R. Saral, and W. H. Burns. 1980. Pathogenicity of Candida tropicalis and Candida albicans after gastrointestinal inoculation in mice. Infection and Immunity 29:808-813.
32. Wingard, J. R., J. D. Dick, W. G. Merz, G. R. Sandford, R. Saral, and W. H. Burns. 1982. Differences in virulence of clinical isolates of Candida tropicalis and Candida albicans in mice. Infection and Immunity 37:833-836.
33. Sandford, G. R., W. G. Merz, J. R. Wingard, P. Charache, and R. Saral. 1980. The Value of Fungal Surveillance Cultures as Predictors of Systemic Fungal Infections. Journal of Infectious Diseases 142:503-509.
34. Wingard, J. R. 1995. Importance of Candida Species Other than C. albicans as Pathogens in Oncology Patients. Clinical Infectious Diseases 20:115-125.
35. Kontoyiannis, D. P., I. Vaziri, H. A. Hanna, M. Boktour, J. Thornby, R. Hachem, G. P. Bodey, and I. I. Raad. 2001. Risk Factors for Candida tropicalis fungemia in patients with cancer. Clin. Infect. Dis. 33:1676-1681.
36. Sandven, P., L. Bevanger, A. Digranes, P. Gaustad, H. H. Haukland, and M. Steinbakk. 1998. Constant low rate of fungemia in norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin. Microbiol. 36:3455-3459.
37. Ghannoum, M. A., R. J. Jurevic, P. K. Mukherjee, F. Cui, M. Sikaroodi, A. Naqvi, and P. M. Gillevet. 2010. Characterization of the Oral Fungal Microbiome (Mycobiome) in Healthy Individuals. PLoS Pathog 6:e1000713.
38. Maccallum, D. M. 2012. Hosting infection: experimental models to assay Candida virulence. Int J Microbiol 2012:363764.
39. Levy, I., L. G. Rubin, S. Vasishtha, V. Tucci, and S. K. Sood. 1998. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin. Infect. Dis. 26:1086-1088.
40. Almirante, B., D. Rodriguez, M. Cuenca-Estrella, M. Almela, F. Sanchez, J. Ayats, C. Alonso-Tarres, J. L. Rodriguez-Tudela, and A. Pahissa. 2006. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: casecontrol population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin. Microbiol 44:1681-1685.
41. Sanchez, V., J. A. Vazquez, D. Barth-Jones, L. Dembry, J. D. Sobel, and M. J. Zervos. 1993. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am. J Med 94:577-582.
42. Hernandez-Castro, R., S. Arroyo-Escalante, E. M. Carrillo-Casas, D. Moncada-Barron, E. Alvarez-Verona, L. Hernandez-Delgado, P. Torres-Narvaez, and A. Lavalle-Villalobos. 2010. Outbreak of Candida parapsilosis in a neonatal intensive care unit: a health care workers source. Eur. J Pediatr. 169:783-787.
43. Arendrup, M. C. 2010. Epidemiology of invasive candidiasis. Curr. Opin. Crit Care 16:445-452.
44. Xu, J. and T. G. Mitchell. 2003. Geographical differences in human oral yeast flora. Clin. Infect Dis 36:221-224.
45. Yildirim, M., I. Sahin, A. Kucukbayrak, D. Ozdemir, M. Tevfik Yavuz, S. Oksuz, and S. Cakir. 2007. Hand carriage of Candida species and risk factors in hospital personnel. Mycoses 50:189-192.
46. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin. Microbiol 46:2620-2629.
47. Garcia-Effron, G., S. K. Katiyar, S. Park, T. D. Edlind, and D. S. Perlin. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312.
48. Pappas, P. G., C. M. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. De Waele, J. A. Vazquez, B. F. Dupont, D. L. Horn, L. Ostrosky-Zeichner, A. C. Reboli, B. Suh, R. Digumarti, C. Wu, L. L. Kovanda, L. J. Arnold, and D. N. Buell. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect Dis 45:883-893.
49. Kuse, E. R., P. Chetchotisakd, C. A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, J. S. Sekhon, A. Freire, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. J. Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, and O. A. Cornely. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519-1527.
50. Reboli, A. C., C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, and T. J. Walsh. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl.J. Med. 356:2472-2482.
51. Arendrup, M. C., J. Bille, E. Dannaoui, M. Ruhnke, C. P. Heussel, and C. Kibbler. 2012. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant. 47:1030-1045.
52. Jensen, R. H. and M. C. Arendrup. 2011. Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species. J Clin. Microbiol 49:549-556.
53. Pfaller, M. A., M. Castanheira, S. R. Lockhart, A. M. Ahlquist, S. A. Messer, and R. N. Jones. 2012. Frequency of Decreased Susceptibility and Resistance to Echinocandins Among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata: Results from the SENTRY Antimicrobial Surveillance Program (2006-2010) and the Centers for Disease Control and Prevention Population-Based Surveillance (2008-2010). Journal of Clinical Microbiology
54. Baixench, M. T., N. Aoun, M. Desnos-Ollivier, D. Garcia-Hermoso, S. Bretagne, S. Ramires, C. Piketty, and E. Dannaoui. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
55. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
56. Cuenca-Estrella, M., A. Gomez-Lopez, I. Cuesta, O. Zaragoza, E. Mellado, and J. L. Rodriguez-Tudela. 2011. Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 55:1794-1797.
57. Chapeland-Leclerc, F., C. Hennequin, N. Papon, T. Noel, A. Girard, G. Socie, P. Ribaud, and C. Lacroix. 2010. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother. 54:1360-1362.
58. Pfeiffer, C. D., G. Garcia-Effron, A. K. Zaas, J. R. Perfect, D. S. Perlin, and B. D. Alexander. 2010. Breakthrough invasive candidiasis in patients on micafungin. J Clin. Microbiol 48:2373-2380.
59. Moran, G. P., D. Sanglard, S. M. Donnelly, D. B. Shanley, D. J. Sullivan, and D. C. Coleman. 1998. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 42:1819-1830.
60. Sanglard, D., A. Coste, and S. Ferrari. 2009. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res. 9:1029-1050.
61. Li, X., N. Brown, A. S. Chau, J. L. Lopez-Ribot, M. T. Ruesga, G. Quindos, C. A. Mendrick, R. S. Hare, D. Loebenberg, B. DiDomenico, and P. M. McNicholas. 2004. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 53:74-80.
62. Warrilow, A. G. S., J. G. L. Mullins, C. M. Hull, J. E. Parker, D. C. Lamb, D. E. Kelly, and S. L. Kelly. 2012. S279 Point Mutations in Candida albicans Sterol 14-alfa Demethylase (CYP51) Reduce In Vitro Inhibition by Fluconazole. Antimicrobial Agents and Chemotherapy 56:2099-2107.
63. Garcia-Effron, G., D. P. Kontoyiannis, R. E. Lewis, and D. S. Perlin. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52:4181-4183.
64. Garcia-Effron, G., S. Park, and D. S. Perlin. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
65. Arendrup, M. C., D. S. Perlin, R. H. Jensen, S. J. Howard, J. Goodwin, and W. Hope. 2012. Differential In vivo activity of Anidulafungin, Caspofungin and Micafungin against C. glabrata with and without FKS resistance mutations. Antimicrob Agents Chemother.
66. Slater, J. L., S. J. Howard, A. Sharp, J. Goodwin, L. M. Gregson, A. Alastruey-Izquierdo, M. C. Arendrup, P. A. Warn, D. S. Perlin, and W. W. Hope. 2011. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Chemother. 55:3075-3083.
67. Garcia-Effron, G., S. Lee, S. Park, J. D. Cleary, and D. S. Perlin. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-{beta}-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
68. Garcia-Effron, G., D. J. Chua, J. R. Tomada, J. Dipersio, D. S. Perlin, M. Ghannoum, and H. Bonilla. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother. 54:2225-2227.
69. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
70. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
71. Castanheira, M., L. N. Woosley, D. J. Diekema, S. A. Messer, R. N. Jones, and M. A. Pfaller. 2010. Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains. Antimicrobial Agents and Chemotherapy 54:2655-2659.
72. Costa-de-Oliveira, S., M. Marcos, R. M. Silva, Pinto E Silva, R. Rocha, A. Amorim, R. A. Goncalves, and C. Pina-Vaz. 2011. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob Agents Chemother. 55:1312-1314.
73. Arendrup, M. C., M. Cuenca-Estrella, J. P. Donnelly, C. Lass-Florl, and J. L. Rodriguez-Tudela. 2009. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob. Agents Chemother. 53:2704-2705.
74. Rodriguez-Tudela, J. L., M. C. Arendrup, F. Barchiesi, J. Bille, E. Chryssanthou, M. Cuenca-Estrella, E. Dannaoui, D. W. Denning, J. P. Donnelly, F. Dromer, W. Fegeler, C. Lass-Florl, C. B. Moore, M. Richardson, P. Sandven, A. Velegraki, and P. E. Verweij. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol Infect. 14:398-405.
75. Arendrup, M. C., M. Cuenca-Estrella, J. P. Donnelly, W. Hope, C. Lass-Florl, J. L. Rodriguez-Tudela, and The European committee on antimicrobial susceptibility testing-subcommittee on antifungal susceptibility testing (EUCASTAFST). 2011. EUCAST technical note on posaconazole*. Clinical Microbiology and Infection 17:E16-E17.
76. Arendrup, M. C., E. Chryssanthou, P. Gaustad, M. Koskela, P. Sandven, and V. Fernandez. 2007. Diagnostics of fungal infections in the Nordic countries: we still need to improve! Scand.J. Infect. Dis. 39:337-343.
77. Arendrup, M. C. and M. A. Pfaller. 2012. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob Agents Chemother. 56:3965-3968.
78. Verweij, P. E., S. J. Howard, W. J. Melchers, and D. W. Denning. 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
79. Arendrup, M. C., M. Cuenca-Estrella, C. Lass-Florl, and W. W. Hope. 2012. EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin. Microbiol Infect 18:E248-E250.
80. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin. Microbiol 46:2620-2629.
81. Arendrup, M. C., S. Park, S. Brown, M. Pfaller, and D. S. Perlin. 2011. Evaluation of Caspofungin and Micafungin CLSI M44-A2 Disk Diffusion and associated breakpoints testing using a well characterized panel of wild type and fks hot spot mutant Candida isolates. Antimicrob Agents Chemother. 55:1891-1895.
82. Garcia-Effron, G., S. Park, and D. S. Perlin. 2011. Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob Agents Chemother. 55:2245-2255.
83. Alastruey-Izquierdo, A., A. Gomez-Lopez, M. C. Arendrup, C. Lass-Florl, W. W. Hope, D. S. Perlin, J. L. Rodriguez-Tudela, and M. Cuenca-Estrella. 2012. Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J Clin. Microbiol 50:2509-2512.
84. Arendrup, M. C., M. Cuenca-Estrella, C. Lass-Florl, and W. Hope. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol Infect 18:E246-E247.
85. Chen, S., M. Slavin, Q. Nguyen, D. Marriott, E. G. Playford, D. Ellis, and T. Sorrell. 2006. Active surveillance for candidemia, Australia. Emerg. Infect. Dis. 12:1508-1516.
86. Hajjeh, R. A., A. N. Sofair, L. H. Harrison, G. M. Lyon, B. A. Arthington-Skaggs, S. A. Mirza, M. Phelan, J. Morgan, W. Lee-Yang, M. A. Ciblak, L. E. Benjamin, L. T. Sanza, S. Huie, S. F. Yeo, M. E. Brandt, and D. W. Warnock. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin. Microbiol. 42:1519-1527.
87. Cleveland, A. A., M. M. Farley, L. H. Harrison, B. Stein, R. Hollick, S. R. Lockhart, S. S. Magill, G. Derado, B. J. Park, and T. M. Chiller. 2012. Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results from Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011. Clinical Infectious Diseases
88. Kibbler, C. C., S. Seaton, R. A. Barnes, W. R. Gransden, R. E. Holliman, E. M. Johnson, J. D. Perry, D. J. Sullivan, and J. A. Wilson. 2003. Management and outcome of bloodstream infections due to Candida species in England and Wales. J. Hosp. Infect. 54:18-24.
89. Colombo, A. L., M. Nucci, B. J. Park, S. A. Nouer, B. rthington-Skaggs, D. A. da Matta, D. Warnock, and J. Morgan. 2006. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J. Clin. Microbiol. 44:2816-2823.
90. Sandven, P., L. Bevanger, A. Digranes, H. H. Haukland, T. Mannsaker, and P. Gaustad. 2006. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 44:1977-1981.
91. Nordøy, I. Candidaemia in Norway. Conference abstract. Trends in Medical Mycology. 19-10-2009.
92. Poikonen, E., O. Lyytikainen, V. J. Anttila, and P. Ruutu. 2003. Candidemia in Finland, 1995-1999. Emerg. Infect. Dis. 9:985-990.
93. Poikonen, E., O. Lyytikainen, V. J. Anttila, I. Koivula, J. Lumio, P. Kotilainen, H. Syrjala, and P. Ruutu. 2010. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC. Infect Dis 10:312.
94. Klingspor, L., E. Tornqvist, A. Johansson, B. Petrini, U. Forsum, and G. Hedin. 2004. A prospective epidemiological survey of candidaemia in Sweden. Scand. J Infect. Dis. 36:52-55.
95. Arendrup, M. C., K. Fuursted, B. Gahrn-Hansen, H. C. Schonheyder, J. D. Knudsen, I. M. Jensen, B. Bruun, J. J. Christensen, and H. K. Johansen. 2008. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 14:487-494.
96. Pfaller, M. A., A. Espinel-Ingroff, E. Canton, M. Castanheira, M. Cuenca-Estrella, D. J. Diekema, A. Fothergill, J. Fuller, M. Ghannoum, R. N. Jones, S. R. Lockhart, E. Martin-Mazuelos, M. S. Melhem, L. Ostrosky-Zeichner, P. Pappas, T. Pelaez, J. Peman, J. Rex, and M. W. Szeszs. 2012. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin. Microbiol 50:2040-2046.
97. Pfaller, M. A. and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
98. Rex, J. H., C. R. Cooper, Jr., W. G. Merz, J. N. Galgiani, and E. J. Anaissie. 1995. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother. 39:906-909.
99. Clancy, C. J. and M. H. Nguyen. 1999. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother. 43:1289-1290.
100. Canton, E., J. Peman, M. Gobernado, A. Viudes, and A. Espinel-Ingroff. 2004. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother. 48:2477-2482.
101. Jensen, R. H., Johansen, H. K., and Arendrup, M. C. Stepwise development of homozygous S80P substitution in Fks1p conferring echinocandin resistance in Candida tropicalis. 2013. Antimicrob Agents Chemother. 57:614-17.
102. Horvath, L. L., B. J. George, C. K. Murray, L. S. Harrison, and D. R. Hospenthal. 2004. Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for candida growth detection. J. Clin. Microbiol. 42:115-118.
103. Klingspor, L., S. A. Muhammed, and V. Ozenci. 2012. Comparison of the two blood culture systems, Bactec 9240 and BacT/Alert 3D, in the detection of Candida spp. and bacteria with polymicrobial sepsis. Eur. J Clin. Microbiol Infect Dis 31:2983-87.
104. Ericson, E. L., L. Klingspor, M. Ullberg, and V. Ozenci. 2012. Clinical comparison of the Bactec Mycosis IC/F, BacT/Alert FA, and BacT/Alert FN blood culture vials for the detection of candidemia. Diagn. Microbiol Infect Dis 73:153-156.
105. Cateau, E., A. S. Cognee, T. C. Tran, E. Vallade, M. Garcia, S. Belaz, C. Kauffmann-Lacroix, and M. H. Rodier. 2012. Impact of yeast-bacteria coinfection on the detection of Candida sp. in an automated blood culture system. Diagn. Microbiol Infect Dis 72:328-331.
106. Brillowska-Dabrowska, A., O. Bergmann, I. M. Jensen, J. O. Jarlov, and M. C. Arendrup. 2010. Typing of Candida isolates from patients with invasive infection and concomitant colonization. Scand. J Infect. Dis. 42:109-113.
107. Dalle, F., N. Franco, J. Lopez, O. Vagner, D. Caillot, P. Chavanet, B. Cuisenier, S. Aho, S. Lizard, and A. Bonnin. 2000. Comparative genotyping of Candida albicans bloodstream and nonbloodstream isolates at a polymorphic microsatellite locus. J Clin. Microbiol 38:4554-4559.
108. Lass-Florl, C., E. Gunsilius, G. Gastl, M. Englisch, G. Koch, H. Ulmer, M. P. Dierich, and A. Petzer. 2003. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Ann. Hematol. 82:565-569.
109. Lortholary, O., M. Desnos-Ollivier, K. Sitbon, A. Fontanet, S. Bretagne, and F. Dromer. 2011. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 55:532-538.
110. Hachem, R., H. Hanna, D. Kontoyiannis, Y. Jiang, and I. Raad. 2008. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112:2493-2499.
111. Tortorano, A. M., J. Peman, H. Bernhardt, L. Klingspor, C. C. Kibbler, O. Faure, E. Biraghi, E. Canton, K. Zimmermann, S. Seaton, and R. Grillot. 2004. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J Clin. Microbiol. Infect. Dis. 23:317-322.
112. Ortega, M., F. Marco, A. Soriano, M. Almela, J. A. Martinez, C. Pitart, and J. Mensa. 2010. Candida spp. bloodstream infection: influence of antifungal treatment on outcome. J Antimicrob Chemother. 65:562-568.
113. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
114. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645.
115. Parkins, M. D., D. M. Sabuda, S. Elsayed, and K. B. Laupland. 2007. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 60:613-618.
116. Klevay, M. J., E. J. Ernst, J. L. Hollanbaugh, J. G. Miller, M. A. Pfaller, and D. J. Diekema. 2008. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn. Microbiol Infect Dis 60:273-277.
117. Kludze-Forson, M., G. A. Eschenauer, C. J. Kubin, P. Della-Latta, and S. W. Lam. 2010. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Med Mycol 48:436-439.
118. Das, I., P. Nightingale, M. Patel, and P. Jumaa. 2011. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis 15:e759-e763.
119. Andes, D. R., N. Safdar, J. W. Baddley, G. Playford, A. C. Reboli, J. H. Rex, J. D. Sobel, P. G. Pappas, and B. J. Kullberg. 2012. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect Dis 54:1110-1122.
120. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, Jr., T. F. Calandra, J. E. Edwards, Jr., S. G. Filler, J. F. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
121. Holzknecht, B. J., J. Thorup, M. C. Arendrup, S. E. Andersen, M. Steensen, P. Hesselfeldt, J. M. Nielsen, and J. D. Knudsen. 2011. Decreasing candidaemia rate in abdominal surgery patients after introduction of fluconazole prophylaxis*. Clin. Microbiol Infect 17:1372-1380.
122. Crump, K. R. and T. D. Edlinds. 2004. Agricultural Fungicides May Select for Azole Antifungal Resistance in Pathogenic Candida. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC 2004, Oct 30-Nov 2. M-1684.